April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
Efficacy of Topical Bromfenac (0.09%) as an Adjunctive Therapy for Patients With Neovascular Age-Related Macular Degeneration
Author Affiliations & Notes
  • S. A. Zweifel
    Manhattan Eye, Ear and Throat Hospital, LuEsther T.Mertz Retinal Research Center, New York, New York
    Department of Ophthalmology, University Hospital of Zurich, Zurich, Switzerland
  • S. Khan
    Department of Ophthalmology, New York University Medical Center, New York, New York
  • M. Engelbert
    Manhattan Eye, Ear and Throat Hospital, LuEsther T.Mertz Retinal Research Center, New York, New York
    Edward S. Harkness Eye Institute, Columbia University, New York, New York
  • K. B. Freund
    Edward S. Harkness Eye Institute, Columbia University, New York, New York
    Vitreous Retina Macula Consultants of New York, New York, New York
  • Footnotes
    Commercial Relationships  S.A. Zweifel, None; S. Khan, None; M. Engelbert, Genentech, C; K.B. Freund, Genentech, C.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 5006. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S. A. Zweifel, S. Khan, M. Engelbert, K. B. Freund; Efficacy of Topical Bromfenac (0.09%) as an Adjunctive Therapy for Patients With Neovascular Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2009;50(13):5006.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To assess the efficacy of topical bromfenac (0.09%) as an adjunctive therapy for patients with neovascular age-related macular degeneration (AMD) demonstrating persistent exudation despite monthly intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy.

Methods: : Twenty-one consecutive patients (22 eyes) who manifested persistent subretinal and/or intraretinal fluid after at least three monthly intravitreal injections of ranibizumab or bevacizumab were prescribed topical bromfenac (0.09%) ophthalmic solution twice daily for two months. The efficacy of topical bromfenac was evaluated by comparing visual acuity (log MAR and Snellen equivalent) and masked readings of spectral domain optical coherence tomography (OCT) center-point retinal thickness, height of pigment epithelial detachment (when present), and central 6mm² (128x512 A-scan) volume measurements at baseline and at one and two months following the initiation of combined treatment.

Results: : The mean visual acuity logMAR (Snellen equivalent) at baseline was 0.51±0.35 (20/95) and did not change significantly after 1 month 0.53±0.35 (p=0.68, paired student t-test) or 2 months 0.52±0.34 (p=0.75) following the initiation of combined treatment. The mean central retinal thickness was 311µm at baseline, 308µm (p=0.73, paired student t-test) after one month, and 299µm (p=0.34) after two months. The comparison of the macular volume did not show any statistically significant change. In 20 eyes of 19 patients manifesting a PED, the mean PED height was 275µm at baseline, 271µm (p=0.33, paired student t-test) at one month, and 274µm (p= 0.76) at two months. There were no adverse events associated with the extended topical administration of topical bromfenac.

Conclusions: : In patients with neovascular AMD manifesting persistent exudation despite monthly intravitreal anti-VEGF therapy, we could not detect a beneficial effect of adding topical bromfenac (0.09%) over two months.

Keywords: age-related macular degeneration • drug toxicity/drug effects • injection 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×